The pandemic may have brought with it growth opportunities for the healthcare and life sciences industry but it has also upped the intensity of a range of business risks, and investors are now looking at things via a different lens when it comes to integrity due diligence.
At a recent webinar, senior executives of Kroll, a leading global provider of services and digital products related to governance, risk and transparency, outlined the “massive shift” underway in the focus and questions being asked while undertaking